AMGEN INC (AMGN) Stock Price, Quote, News and Overview
NASDAQ:AMGN - Nasdaq - US0311621009 - Common Stock - Currency: USD
AMGN Quote, Performance and Key Statistics
287.1
+0.09 (+0.03%)
The current stock price of AMGN is 287.1 USD. In the past month the price increased by 4.08%. In the past year, price decreased by -5.88%.
AMGN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.25 | 331.15B | ||
| GILD | GILEAD SCIENCES INC | 14.27 | 137.40B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 113.97B | ||
| REGN | REGENERON PHARMACEUTICALS | 10.9 | 52.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 40.16B | ||
| ARGX | ARGENX SE - ADR | 100.97 | 35.45B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.58 | 27.78B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.48B | ||
| NTRA | NATERA INC | N/A | 22.60B | ||
| BIIB | BIOGEN INC | 8.24 | 19.10B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 14.65B | ||
| UTHR | UNITED THERAPEUTICS CORP | 12.76 | 14.42B |
Related stock screener links
About AMGN
Company Profile
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company is headquartered in Thousand Oaks, California and currently employs 28,000 full-time employees. The company discovers, develops, manufactures and delivers medicines for the toughest diseases. The company focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. The company operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. The company markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. The company markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. The company markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
Company Info
AMGEN INC
One Amgen Center Drive
Thousand Oaks CALIFORNIA 91320 US
CEO: Robert A. Bradway
Employees: 28000
Phone: 18054471000
AMGEN INC / AMGN FAQ
What is the stock price of AMGEN INC today?
The current stock price of AMGN is 287.1 USD. The price increased by 0.03% in the last trading session.
What is the ticker symbol for AMGEN INC stock?
The exchange symbol of AMGEN INC is AMGN and it is listed on the Nasdaq exchange.
On which exchange is AMGN stock listed?
AMGN stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for AMGEN INC stock?
39 analysts have analysed AMGN and the average price target is 320.24 USD. This implies a price increase of 11.54% is expected in the next year compared to the current price of 287.1. Check the AMGEN INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is AMGEN INC worth?
AMGEN INC (AMGN) has a market capitalization of 154.38B USD. This makes AMGN a Large Cap stock.
How many employees does AMGEN INC have?
AMGEN INC (AMGN) currently has 28000 employees.
What are the support and resistance levels for AMGEN INC (AMGN) stock?
AMGEN INC (AMGN) has a support level at 284.64 and a resistance level at 318.08. Check the full technical report for a detailed analysis of AMGN support and resistance levels.
Is AMGEN INC (AMGN) expected to grow?
The Revenue of AMGEN INC (AMGN) is expected to grow by 6.24% in the next year. Check the estimates tab for more information on the AMGN EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy AMGEN INC (AMGN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of AMGN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of AMGN, evaluating the profitability, health, valuation and growth aspects
- AMGEN INC (AMGN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- AMGEN INC (AMGN) Sales and EPS estimates to see what analysts future expectations are.
- AMGEN INC (AMGN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- AMGEN INC (AMGN) Insider and Institutional Ownership to learn about the owners and their transactions.
- AMGEN INC (AMGN) Stock Chart to make your own analysis
- AMGEN INC (AMGN) Latest news and press-releases to stay up to date.
Does AMGEN INC (AMGN) stock pay dividends?
AMGEN INC (AMGN) has a dividend yield of 3.36%. The yearly dividend amount is currently 9.01. Check the full fundamental report for a detailed analysis of AMGN dividend history, reliability and sustainability.
When does AMGEN INC (AMGN) report earnings?
AMGEN INC (AMGN) will report earnings on 2025-08-04, before the market open.
What is the Price/Earnings (PE) ratio of AMGEN INC (AMGN)?
The PE ratio for AMGEN INC (AMGN) is 13.83. This is based on the reported non-GAAP earnings per share of 20.76 and the current share price of 287.1 USD. Check the full fundamental report for a full analysis of the valuation metrics for AMGN.
What is the Short Interest ratio of AMGEN INC (AMGN) stock?
The outstanding short interest for AMGEN INC (AMGN) is 2.68% of its float. Check the ownership tab for more information on the AMGN short interest.
AMGN Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to AMGN. When comparing the yearly performance of all stocks, AMGN is a bad performer in the overall market: 74.38% of all stocks are doing better.
AMGN Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to AMGN. AMGN scores excellent on profitability, but there are some minor concerns on its financial health.
AMGN Financial Highlights
Over the last trailing twelve months AMGN reported a non-GAAP Earnings per Share(EPS) of 20.76. The EPS increased by 11.43% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 17.39% | ||
| ROA | 6.64% | ||
| ROE | 95.59% | ||
| Debt/Equity | 8.7 |
AMGN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 73% to AMGN. The Buy consensus is the average rating of analysts ratings from 39 analysts.
For the next year, analysts expect an EPS growth of 7.16% and a revenue growth 6.24% for AMGN